1 October 2015 |
| 07:30-19:00 | | Registration
|
| 08:00-11:00 | | Working Group WG1 - ESPE Bone and Growth Plate (BGP) Working Group Chair(s): Ola Nilsson (Stockholm, Sweden) & Gabriele Häusler (Vienna, Austria) Hall 3
|
| 08:00 | WG1.1 | Short stature: blame the chondrocyte |
| 08:30 | WG1.2 | The role of NFkB in growth plate chondrogenesis |
| 09:00 | | Coffee Break |
| 09:30 | WG1.3 | Genetics of juvenile osteoporosis |
| 10:00 | WG1.4 | Bone tissue characteristics in pediatric bone disease |
| 10:30 | WG1.5 | Fracture prevention in cystic fibrosis |
| 08:00-11:00 | | Working Group WG2 - ESPE Working Group on Diabetes Technology and Therapeutics Chair(s): Moshe Phillip (Petah Tikva, Israel) & Tadej Battelino (Ljubljana, Slovenia) Hall 1
|
| 08:00 | | Introductions |
| 08:05 | WG2.1 | New technologies in treating patients with type 2 diabetes |
| 08:30 | WG2.2 | Debate: Are genetic tests necessary before starting a treatment of a patient with Neonatal Diabetes? |
| 08:30 | WG2.3 | Debate: Are genetic tests necessary before starting a treatment of a patient with Neonatal Diabetes? |
| 09:10 | | Coffee Break |
| 09:30 | WG2.4 | Debate: Blood glucose monitoring - which is the better: continuous real-time or episodic real-time on demand? |
| 09:31 | WG2.5 | Debate: Blood glucose monitoring - which is the better: continuous real-time or episodic real-time on demand? |
| 10:10 | WG2.6 | Type 2 diabetes mellitus in adolescence |
| 10:35 | WG2.7 | The rationale and potential role of surgery in the treatment of adolescent diabetes |
| 08:00-11:00 | | Working Group WG3 - ESPE Working Group on Disorders of Sex Development (DSD) Chair(s): Paul Martin Holterhus (Kiel, Germany) & Anna Nordenström (Stockholm, Sweden) Hall 2
|
| 08:00 | | Welcome |
| 08:00 | WG3.1 | Maternal, placental and fetal steroid hormone synthesis: the key facts for understanding DSDs |
| 08:30 | WG3.2 | DSD in Indonesia: the course of psychological development in late identified patients |
| 09:00 | | Coffee Break |
| 09:30 | WG3.3 | Work accomplished by the European Reference Network |
| 10:15 | WG3.4 | I-DSD and I-CAH registry update |
| 10:30 | WG3.5 | EU-Study: dsd-LIFE |
| 10:45 | | DSD Open Business Meeting |
| 08:00-11:00 | | Working Group WG4 - ESPE Obesity Working Group (OWG) Chair(s): Jesús Argente (Madrid, Spain) & Bessie Spiliotis (Patras, Greece) Hall 7
|
| 08:00 | WG4.1 | The endocrine role of brown adipose tissue |
| 08:40 | WG4.2 | A monomeric peptide triagonist for the treatment of obesity and diabetes |
| 09:20 | | Coffee Break |
| 09:40 | WG4.3 | Genetic approach to understanding severe early-onset childhood obesity |
| 10:20 | WG4.4 | Understanding gene-diet interactions as an approach for the treatment of obesity |
| 08:00-11:00 | | Working Group WG5 - ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG) Chair(s): Marco Cappa (Rome, Italy) & Charles Sultan (Montpellier, France) Hall 4
|
| 08:00 | WG5.1 | Impact of malignancies and their treatment on reproductive function in girls |
| 08:30 | WG5.2 | Preservation of fertility pre-therapy |
| 09:00 | WG5.3 | Restoration of fertility in cancer adolescents after chemotherapy |
| 09:30 | | Coffee Break |
| 10:00 | WG5.4 | Diagnosis and management of endometriosis in adolescence |
| 10:30 | WG5.5 | Uterus transplantation with live births – an update |
| 08:00-11:00 | | Working Group WG6 - ESPE Working Group on Turner Syndrome (TS) Chair(s): Siska Verlinde & Malcolm Donaldson / Ewa Malecka-Tendera & Jenielle van Alfen Hall 5
|
| 08:00 | | Welcome |
| 08:05 | WG6.1 | Incidental prenatal diagnosis of Turner Syndrome, perspectives of parents and professionals |
| 08:45 | WG6.2 | The challenges of prenatal diagnosis: the experience of a supportive group for parents of children with TS |
| 09:15 | | Coffee Break |
| 09:30 | WG6.3 | Impact of age at start and GH dose for height gain and age at adult height in TS girls |
| 10:00 | WG6.4 | Management of middle ear and hearing problems in Turner's syndrome - how can we do better? |
| 10:30 | WG6.5 | Report on the progress and difficulties on transdermal Estradiol supplementation in Europe |
| 11:15-11:30 | | Opening Ceremony Hall 1
|
| 11:30-12:00 | | Plenary 1 Chair(s): Ragnar Hanas (Uddevalla, Sweden) & Luis Castaño (Bilbao, Spain) Joint ESPE-ISPAD Session Hall 1
|
| 11:30 | PL1 | Genetic and environmental determinants of type 1 diabetes |
| 12:00-12:30 | | Plenary 2 Chair(s): Ragnar Hanas (Uddevalla, Sweden) & Luis Castaño (Bilbao, Spain) Joint ESPE-ISPAD Session Hall 1
|
| 12:00 | PL2 | New advances in monogenetic diabetes |
| 12:30-14:00 | | Lunch, Visit to Posters and Exhibition
|
| 12:30-13:30 | | P1 Mini-Poster Presentations
|
| | Adrenal: P1-1 to P1-11 |
| | Bone: P1-12 to P1-22 |
| | Diabetes: P1-23 to P1-33 |
| | Growth Hormone: P1-78 to P1-88 |
| | Perinatal: P1-100 to P1-110 |
| 12:45-13:45 | | Industry Sponsored Satellite Symposium 1
|
| 14:00-15:30 | | Symposium 1 - The effect of hormonal abnormalities on Neurocognition Chair(s): Jesús Argente (Madrid, Spain) & George Chrousos (Athens, Greece) Hall 3
|
| 14:00 | S1.1 | The effect of thyroid hormones on the brain |
| 14:30 | S1.2 | The effect of diabetes mellitus on neurocognition |
| 15:00 | S1.3 | The effects of growth hormone and anabolic androgenic steroids on the brain |
| 14:00-15:30 | | Symposium 2 - Adipose tissue: Beyond classical concepts Chair(s): Martin Wabistch (Ulm, Germany) & Antje Körner (Leipzig, Germany) Hall 5
|
| 14:00 | S2.1 | Brown adipose tissue and its therapeutic potential |
| 14:30 | S2.2 | Is brown adipose tissue relevant to paediatrics? |
| 15:00 | S2.3 | Lipodystrophies: new approaches for diagnostic workup and treatment |
| 14:00-15:30 | | Symposium 3 - Disorders of sex development: An update Chair(s): Nils Krone (Sheffield, UK) & Olaf Hiort (Luebeck, Germany) Hall 2
|
| 14:00 | S3.1 | Novel genes identified in male and female sex development |
| 14:30 | S3.2 | Decision Making in DSD: Development of a Decision Support Tool. |
| 15:00 | S3.3 | Genetic and enviromental disruption of testicular function |
| 14:00-15:30 | | Symposium 4 - Management of thyroid disorders: Current best practice Chair(s): Jan-Maarten Wit (Leiden, The Netherlands) & Annette Greuters-Kieslich (Berlin, Germany) Hall 1
|
| 14:00 | S4.1 | Screening, diagnosis and management of congenital hypothyroidism |
| 14:30 | S4.2 | Management of hyperthyroidism in children |
| 15:00 | S4.3 | Genetics of congenital hypothyroidism and associated problems |
| 15:30-16:00 | | Coffee Break
|
| 16:00-17:00 | | Meet the Expert Sessions
|
| MTE1.1 | Management of adrenal tumours |
| MTE2.1 | Translation of diabetes technologies to clinical practice |
| MTE3.1 | Challenges in the management of short stature |
| MTE4.1 | Use of hormone replacement in females with endocrine disorders |
| 16:00-17:00 | | Controversies 1: Debate - Is bariatric surgery the management of choice for obese adolescents? Chair(s): Wieland Kiess (Leipzig, Germany) & Bessie Spiliotis (Athens, Greece) Hall 4
|
| | For the Motion |
| | Against the Motion |
| 16:00-17:00 | | Yearbook of Paediatric Endocrinology Chair(s): Franco Chiarelli (Chieti, Italy) Hall 1
|
| YB1.1 | Obesity and weight regulation |
| YB1.2 | Type 2 diabetes, metabolic syndrome and lipids |
| YB1.3 | Type 1 diabetes |
| YB1.4 | Evidence based medicine in pediatric endocrinology |
| YB1.5 | Editor's choice |
| 17:15-18:45 | | Industry Sponsored Satellite Symposium 2 - 4
|
| 18:45- | | Welcome Reception Exhibition area
|
2 October 2015 |
| 07:30-19:00 | | Registration
|
| 08:00-09:00 | | Meet the Expert Sessions
|
| MTE8.1 | Looking beyond nutritional rickets: From the foetus to the infant |
| MTE5.1 | Management of the adolescent with CAH |
| MTE6.1 | Management of Prader-Willi syndrome in toddlers |
| MTE7.1 | Management of late-effects in the child/adolescent with cancer |
| 09:15-10:15 | | Free Communications 1 - Adrenal Chair(s): Berenice Mendonca (Sao Paulo, Brazil) & Christa Flück (Bern, Switzerland) Hall 2
|
| 09:15 | FC1.1 | A genomic atlas of human gonad and adrenal development |
| 09:25 | FC1.2 | Involvement of the Wnt/beta-catenin pathway, SF1, DAX1 and stem/progenitor cell markers in paediatric adrenocortical tumors (ACTs) |
| 09:35 | FC1.3 | Aldosterone and mineralocorticoid receptor as inducers of immune markers in peripheral blood mononuclear cells: beyond elevating blood pressure |
| 09:45 | FC1.4 | Congenital adrenal hyperplasia due to 21 OH deficiency: final height before and after newborn screening era in Emilia-Romagna region, Italy |
| 09:55 | FC1.5 | Atypical presentation of six patients with mutations in the side chain cleavage enzyme CYP11A1 |
| 10:05 | FC1.6 | An update on noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free foetal DNA in maternal plasma |
| 09:15-10:15 | | Free Communications 2 - Bone & Mineral Metabolism Chair(s): Dov Tosiano (Israel) & Serap Turan (Istanbul, Turkey) Hall 3
|
| 09:15 | FC2.1 | Whole exome sequencing analysis of patients with autosomal recessive hypophophatemic rickets identified mutations in DMP1, ENPP1 and SLC34A3 |
| 09:25 | FC2.2 | Identification of mutations in TBX1 and AIRE in isolated hypoparathyroidism patients |
| 09:35 | FC2.3 | High success of a next generation sequencing panel for the molecular diagnosis of rare skeletal dysplasias |
| 09:45 | FC2.4 | Asfotase alfa: sustained efficacy and tolerability in children with hypophosphatasia treated for 5 years |
| 09:55 | FC2.5 | Methyl donor deficiency impairs differentiation of pre-osteoblasts through disruption of functional interaction between peroxisome proliferator-activated receptor-gamma coactivator-1 alpha and vitamin D receptor |
| 10:05 | FC2.6 | A contextual feature-based recognition approach to quantify trabecular microstructure using 1.5T axial-MRI: an innovative methodology |
| 09:15-10:15 | | Free Communications 3 - Diabetes Chair(s): Alfonso Lechuga (Spain) & Silva Arslanian Hall 4
|
| 09:15 | FC3.1 | RNA-based MAFA over-expression is sufficient to drive human pancreatic duct-derived cells toward a -cell-like phenotype |
| 09:25 | FC3.2 | Experience with molecular diagnosis in 48 cases of neonatal diabetes mellitus using targeted next-generation sequencing |
| 09:35 | FC3.3 | Clinical characteristics and molecular genetic analysis of 6 patients with pancreas aplasia and neonatal diabetes: predominance of PTF1A-enhancer mutations |
| 09:45 | FC3.4 | Wolfram syndrome: natural history and genotype-phenotype correlation based on EURO-WABB Registry show gender differences in disease severity |
| 09:55 | FC3.5 | C-peptide levels and glycemic control in children, adolescents and young adults with type 1 diabetes (TID) |
| 10:05 | FC3.6 | First report of nationwide incidence and prevalence of type 1 diabetes among children in Turkey |
| 09:15-10:15 | | Free Communications 4 - Growth Chair(s): Jovanna Dahlgren & Gary Butler (London, UK) Hall 5
|
| 09:15 | FC4.1 | Heterozygous dominant negative STAT5B variants associated with short stature and GH insensitivity |
| 09:25 | FC4.2 | A recurrent homozygous NDUFB3 mutation, p.Trp22Arg causes a short stature disorder and mitochondrial protein complex I deficiency with a variable metabolic phenotype |
| 09:35 | FC4.3 | An updated and final analysis of a randomised placebo-controlled trial of the effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome |
| 09:45 | FC4.4 | Modulation of GH-1 splicing as potential strategy to rescue growth hormone deficiency type II |
| 09:55 | FC4.5 | Stunted growth after inhaled corticosteroid use during the first 24 months of life |
| 10:05 | FC4.6 | Positive association between height and cancer in the Swedish population |
| 09:15-10:15 | | Free Communications 5 - Endocrine Oncology / Turner Syndrome Chair(s): (Mohammed Maghnie (Genoa, Italy) & Cristina Azcona (Pamplona, Spain) Hall 7
|
| 09:15 | FC5.1 | Resveratrol potentiates growth inhibitory effects of rapamycin in PTEN-deficient lipoma cells by suppressing p70S6 kinase activity |
| 09:25 | FC5.2 | MEN1 syndrome because of combined germline and somatic mosaicism, with important consequences for relatives |
| 09:35 | FC5.3 | Screening in children with Succinate dehydrogenase B (SDHB) mutations: a single centre’s family clinic experience |
| 09:45 | FC5.4 | X chromosome gene dosage and the risk of developing congenital and acquired traits in Turner syndrome: a cross-sectional database analysis of the French national rare disease network |
| 09:55 | FC5.5 | Hereditary Turner syndrome 46,X,rec(X)inv(p21q28) in six women and four generations: estimation of skeletal effects of growth hormone treatment |
| 10:05 | FC5.6 | Anti-Müllerian hormone levels in patients with Turner syndrome: relation to karyotype, pubertal development and growth hormone therapy |
| 09:15-10:15 | | Yearbook of Paediatric Endocrinology Chair(s): Primus Mullis (Bern, Switzerland) Hall 1
|
| YB2.1 | Pituitary and neuroendocrinology |
| YB2.2 | Reproductive Endocrinology |
| YB2.3 | Antenatal and Neonatal Endocrinology |
| YB2.4 | Growth and growth factors |
| YB2.5 | Type 1 diabetes |
| 09:15-10:15 | | New Perspectives Session 1 Chair(s): Cheri Deal (Montreal, Canada) Hall 6
|
| NP1.1 | Pancreatic development using zebrafish as a model |
| NP1.2 | Optogenetic control of neuroendocrine hormone secretion |
| 10:45-11:15 | | Plenary 3 Chair(s): Jean-Claude Carel (Paris, France) & Mehul Dattani (London, UK) Hall 1
|
| 10:45 | PL3 | New advances in human evolution from the analysis of ancient genomes |
| 11:15-12:15 | | ESPE Awards and Activities 1 Chair(s): Anita Hokken-Koelega (Rotterdam, The Netherlands) & Jan Lebl (Prague, Czech Republic) Hall 1
|
| | ESPE Young Investigator Award 1 & 2 – sponsored by Pfizer |
| | ESPE Schools – sponsored by ESPE (Diabetes, Obesity and Metabolism School), Ferring Pharmaceuticals (Summer, Winter and Caucasus & Central Asia Schools), Novo Nordisk Gulf (ASPED-ESPE School), and Pfizer (Maghreb School) |
| | ESPE Fellowships and Sabbatical Leave Programme – sponsored by Novo Nordisk A/S (Research Fellowship), Merck Serono SA (Clinical Fellowship) and Eli Lilly and Company (Sabbatical Leave Programme) |
| | ESPE Hormone Research in Paediatrics Prizes – sponsored by Karger A.G. |
| | ESPE International Award – sponsored by Pfizer |
| | ESPE Research Award – sponsored by Pfizer |
| 12:15-12:45 | | Plenary 4 Chair(s): Jean-Claude Carel (Paris, France) & Mehul Dattani (London, UK) Hall 1
|
| 12:15 | PL4 | Genomic diversity in present day humans: Evolutionary aspects |
| 12:45-14:30 | | Lunch, Visit to the Posters and Exhibition
|
| 12:45-13:45 | | P1 Mini Poster Presentations
|
| | Diabetes: P1-34 to P1-44 |
| | DSD: P1-56 to P1-66 |
| | Growth: P1-89 to P1-99 |
| | Turner & Puberty: P1-133 to P1-143 |
| | Misc: P1-144 to P1-154 |
| 13:15-14:15 | | Industry Sponsored Satellite Symposium 5
|
| 14:15-16:15 | | ESPE Working Group for Paediatic Endocrine Nurse Specialists and Allied Health Professionals (PENSWG) Chair(s): Kate Davies (London, UK) & Christine Derycke (Brussels, Belgium) Hall 6
|
| 14:15 | WG7.1 | Nurse run short stature screening clinic |
| 14:35 | WG7.2 | Quality management initiatives in pediatric endocrinology: Selected case study and clinical initiatives |
| 14:55 | | Q & A from the first two speakers |
| 15:10 | WG7.3 | Getting a patient off of medication due to coaching and care. A case report |
| 15:20 | WG7.4 | Long-term outcome of a male preschooler treated for central precocious puberty |
| 15:30 | WG7.5 | Pan-Canadian experience of pediatric endocrine nurses assisting youth through gender transition |
| 15:40 | | Q & A from the above case study speakers |
| 15:55 | WG7.6 | Sharing Resources: Hypothyroidism |
| 14:30-16:00 | | Symposium 5 - Developmental Programming: Novel concepts Chair(s): Stefano Cianfarani (Rome, Italy) & Ruben Diaz (Spain) Hall 5
|
| 14:30 | S5.1 | Developmental programming of reproductive function: Early life nutritional impacts |
| 15:00 | S5.2 | Transgenerational developmental programming of endocrine disease |
| 15:30 | S5.3 | Intergenerational programming of metabolic disease |
| 14:30-16:00 | | Symposium 6 - Type 2 Diabetes & Obesity Chair(s): Tadej Battelino (Ljubljana, Slovenia) & Jan Lebl (Prague, Czech Republic) Hall 1
|
| 14:30 | S6.1 | Can genotype be used to tailor treatment of obesity? |
| 15:00 | S6.2 | New and old drugs for treatment of type 2 diabetes in children |
| 15:30 | S6.3 | From obesity to type 2 diabetes |
| 14:30-16:00 | | Symposium 7 - Hypogonadotropic hypogonadism: diagnostic and therapeutic approach Chair(s): Nicholas de Roux (Paris, France) & Maria Clemente Hall 2
|
| 14:30 | S7.1 | Early therapeutic approach to the male patient with HH |
| 15:00 | S7.2 | Pubertal induction and fertility prospects in the male |
| 15:30 | S7.3 | Modeling GnRH deficiency with the use of human pluripotent cells |
| 14:30-15:30 | | Controversies 2: Debate - Should pre-natal treatment for CAH be offered? Chair(s): Peter Hindmarsh (London, UK) Hall 4
|
| | For the Motion |
| | Against the Motion |
| 14:30-16:00 | | Special Symposium - Recommendations for surveillance for thyroid cancer in survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group Chair(s): Hanneke van Santen Hall 3
|
| 14:30 | SS1.1 | Introduction of the IGHG-thyroid group, its members and aims |
| 14:35 | SS1.2 | Methodology of the IGHG recommendations |
| 14:45 | SS1.3 | Which cancer survivors are at risk for thyroid cancer; summary of the evidence |
| 15:00 | SS1.4 | Is detection of thyroid cancer in an early stage beneficial ? |
| 15:10 | SS1.5 | Which evaluation modality is most sensitive and specific for detecting thyroid carcinoma in an early stage; summary of the evidence and decision tree analysis. |
| 15:20 | SS1.6 | Pro-Con debate - Arguments in favour of screening survivors at risk with palpation of the neck |
| 15:35 | SS1.6 | Pro - Con Debate: Arguments in favour of screening survivors at risk with thyroid ultrasound |
| 15:50 | SS1.7 | Further steps of the IGHG group; forming a decision aid. |
| 14:30-16:00 | | Special Symposium - Opportunities and challenges in accessing essential medications in low and middle income countries Chair(s): Reiko Horikawa (Japan) Hall 7
|
| 14:30 | SS2.1 | Facilitating Access to Essential Medicines: role of WHO |
| 15:00 | SS2.2 | Bringing essential medicines into low income countries: opportunities and challenges for the pharmaceutical |
| 15:30 | SS2.3 | A model for the sustainable access to medicines for the management of congenital adrenal hyperplasia (CAH) in a low income setting |
| 16:15-17:45 | | ESPE Annual Business Meeting ESPE Members Only
|
| 18:00-19:30 | | Industry Sponsored Satellite Symposium 6 - 8
|
3 October 2015 |
| 07:30-18:30 | | Registration
|
| 08:00-09:00 | | Meet the Expert Sessions
|
| MTE1.2 | Management of adrenal tumours |
| MTE3.2 | Challenges in the management of short stature |
| MTE4.2 | Use of hormone replacement in females with endocrine disorders |
| MTE7.2 | Management of late-effects in the child/adolescent with cancer |
| MTE2.2 | Translation of diabetes technologies to clinical practice |
| 09:15-10:15 | | New Perspectives Session 2 Chair(s): Ze'ev Hochberg (Haifa, Israel) & Gabriele Haeusler Hall 7
|
| NP2.1 | Engineering cartilage |
| NP2.2 | Astrocytes and neuroendocrine control |
| 09:15-10:15 | | New Technologies Session Chair(s): Ken Ong (Cambridge, UK) & Laura De Graff (The Netherlands) Hall 6
|
| NT1 | New technologies in imaging |
| NT2 | Next Generation Sequencing: Implementing the 100,000 genome project for treatment of NHS patients |
| 09:15-10:15 | | Free Communications 6 - Gonads & DSD Chair(s): Tsutomu Ogata (Japan) & John Achermann (London, UK) Hall 1
|
| 09:15 | FC6.1 | Correlation of AR expression and AR transcriptional activity in cultured human genital fibroblasts |
| 09:25 | FC6.2 | A role for DMRT1 in human primary sex-determination |
| 09:35 | FC6.3 | Establishing the role of the steroid backdoor pathway for androgen biosynthesis in the human ovary |
| 09:45 | FC6.4 | Severe 46, XY disorder of sex development (DSD) due to CBX2 isoform 2 mutation is distinct from CBX2.1 deficiency and is likely due to EMX2 dysregulation in the human developing gonad |
| 09:55 | FC6.5 | Characterisation of mutations in the androgen receptor (AR) identified in 38 Brazilian families with complete or partial androgen insensitivity syndrome (AIS) |
| 10:05 | FC6.6 | Frequency of gonadal tumour in complete androgen insensitivity syndrome (CAIS): a retrospective case-series analysis |
| 09:15-10:15 | | Free Communications 7 - Growth promoting therapies Chair(s): Gerhard Binder (Tuebingen, Germany) & Alexander Augusto de Lima Jorge (São Paulo, Brazil) Hall 2
|
| 09:15 | FC7.1 | Safety and effectiveness of Increlex® therapy in children with Laron syndrome and enrolled in the European Increlex® Growth Forum Database (EU-IGFD) in Europe |
| 09:25 | FC7.2 | Topicon™ ThermoMatrix™-mediated passive transdermal delivery of insulin-like growth factor 1 (IGF-1) Across EpidermFT™ full-thickness human skin equivalent (HSE): towards an extended-wear IGF-1 Patch |
| 09:35 | FC7.3 | IGF-I levels, complex formation and igf-bioactivity in growth hormone treated children with Prader-Willi syndrome |
| 09:45 | FC7.4 | A novel reversible albumin-binding growth hormone derivative possesses a promising once-weekly treatment profile in children with growth hormone deficiency |
| 09:55 | FC7.5 | 12 month safety and efficacy of a weekly long-acting growth hormone (GH, MOD-4023) compared to daily recombinant human GH (rh)GH) therapy in pre-pubertal growth hormone deficient children; Phase 2 study – Study CP-4-004 Summary |
| 10:05 | FC7.6 | Pharmacokinetic (PK) and pharmacodynamics (PD) modelling of MOD 4023 (a long-acting human growth hormone (hGH)) in growth hormone deficient (GHD) children |
| 09:15-10:15 | | Free Communications 8 - Obesity Basic Chair(s): Jean-Pierre Chanoine & Carlo Acerini (Cambridge, UK) Hall 3
|
| 09:15 | FC8.1 | DLK1 expression in adipose tissue following fetal growth restriction: relation to visceral fat expansion and catch-up growth in Wistar rats |
| 09:25 | FC8.2 | Apoptosis inhibitor of macrophages (AIM): an anti-inflammatory adipocyte factor in mild adolescent obesity? |
| 09:35 | FC8.3 | Testing the Appetite Suppressing Effects of Vitamin B12 Conjugates of Peptide YY |
| 09:45 | FC8.4 | Severe early-onset obesity caused by bioinactive leptin due to a N103K mutation |
| 09:55 | FC8.5 | Adipocytokines in placenta and cord blood in relation to maternal obesity, and foetal and postnatal growth of the child |
| 10:05 | FC8.6 | Metabolic effects of ADP355, protein-based adiponectin receptor agonist, on mice with high-fat diet induced fatty liver disease |
| 09:15-10:15 | | Free Communications 9 - Beta cell disorders Chair(s): John Gregory (Cardiff, UK) & Ritika Kapoor Hall 4
|
| 09:15 | FC9.1 | Islet δ-cells contribute to the pathobiology of atypical congenital hyperinsulinism |
| 09:25 | FC9.2 | A novel source of mesenchymal stem cells lines from the human neonatal pancreas of patients with congenital hyperinsulinism in infancy |
| 09:35 | FC9.3 | Failure to terminate cell proliferation contributes to the pathobiology of congenital hyperinsulinism in infancy |
| 09:45 | FC9.4 | Novel molecular mechanisms of congenital hyperinsulinism due to autosomal dominant mutations in ABCC8 |
| 09:55 | FC9.5 | The use of glucagon for management of severe-persistent hypoglycaemia in patients with congenital hyperinsulinism |
| 10:05 | FC9.6 | Pharmacokinetics (PK) of a new suspension of glibenclamide for use in young patients and infants with neonatal diabetes |
| 10:45-11:45 | | ESPE Awards and Activities 2 Chair(s): Laura Audí (Barcelona, Spain) & Lars Sävendahl (Stockholm, Sweden) Hall 1
|
| | Henning Andersen Prizes – sponsored by Novo Nordisk A/S |
| | ESPE Research Unit – sponsored by ESPE and Sandoz International GmbH |
| | IFCAH-ESPE award – supported by The International Fund for Research on Congenital Adrenal Hyperplasia |
| | ESPE Outstanding Clinician Award – sponsored by Pfizer |
| | ESPE International Outstanding Clinician Award – sponsored by Pfizer |
| | Andrea Prader Prize – sponsored by Pfizer |
| 11:45-12:15 | | Plenary 5 Chair(s): Lourdes Ibanez Hall 1
|
| 11:45 | PL5 | Ontogeny of FGF21 in the human: Implications for metabolic health |
| 12:30-13:30 | | Yearbook of Paediatric Endocrinology Chair(s): Juliane Léger (Paris, France) Hall 1
|
| YB3.1 | Adrenals |
| YB3.2 | THyroid |
| YB3.3 | Bone, Growth plate and mineral metabolism |
| YB3.4 | Oncology and chronic disease |
| YB3.5 | The Year in Science and Medicine |
| 12:30-13:30 | | Free Communications 10 - Perinatal endocrinology Chair(s): Rod Mitchell (Edinburgh, UK) & Irène Netchine (Paris, France) Hall 2
|
| 12:30 | FC10.1 | Effect of sonic hedgehog signalling on regulation the expression of 11β-HSD2 in the placenta |
| 12:40 | FC10.2 | The altered circulating miRNA profile in maternal obesity associate with pre- and post-natal growth |
| 12:50 | FC10.3 | Circulating miRNA expression profile in pregestational and gestational obesity |
| 13:00 | FC10.4 | Effect of P450 oxidoreductase variants on metabolism by cytochrome P450 proteins |
| 13:10 | FC10.5 | Lack of association between transient hypothyroxinaemia of prematurity and neurodevelopmental and behavioral outcomes in young adulthood |
| 13:20 | FC10.6 | Heterozygous hypomorphic mutation in the INS gene could cause transient neonatal diabetes in extremely low birth weight neonates |
| 12:30-13:30 | | Free Communications 11 - Neuroendocrinology Chair(s): Ivo Arnhold (Sao Paulo, Brazil) & Malcolm Donaldson (Glasgow, Scotland) Hall 3
|
| 12:30 | FC11.1 | Mutations in BRAF are associated with septo-optic dysplasia and cardiofaciocutaneous syndrome |
| 12:40 | FC11.2 | Functional characterisation of a POU1F1 mutation unexpectedly associated with isolated growth hormone deficiency (IGHD): a novel aetiology of IGHD |
| 12:50 | FC11.3 | Next generation sequencing: towards a new clinical frontier in the diagnosis and management of pituitary tumours |
| 13:00 | FC11.4 | Idiopathic multiple pituitary hormone deficiency (IMPHD): radiological and perinatal factors |
| 13:10 | FC11.5 | Endocrinopathy after intracranial germ cell tumours (IGCT) is disease not radiation- related: two decades of surveillance in a large tertiary paediatric cohort |
| 13:20 | FC11.6 | Long-term outcome of patients treated for paediatric Cushing's disease |
| 12:30-13:30 | | Free Communications 12 - Obesity clinical Chair(s): Juan-Pedro Lopez-Siguero & Veronica Mericq Hall 4
|
| 12:30 | FC12.1 | Evaluation of cardiovascular risk in childhood: data from a survey of dyslipidaemic children |
| 12:40 | FC12.2 | Soluble CD163, a circulating marker of macrophage activation, associates with a less favourable metabolic profile in children |
| 12:50 | FC12.3 | Re-classification of childhood obesity by steroid metabolomic disease signature |
| 13:00 | FC12.4 | RM-493, a melanocortin-4 receptor (MC4R) agonist, is being therapeutically evaluated in patients with deficiencies in the Leptin – Proopiomelanocortin (POMC) – MC4R hypothalamic pathway, including Prader-Willi syndrome (PWS) |
| 13:10 | FC12.5 | Link between body mass index and insulin requirement in children and young people with type 1 diabetes mellitus |
| 13:20 | FC12.6 | Initial experience with endoscopically placed duodenal-jejunal bypass liner (Endobarrier®) in morbidly obese adolescents |
| 12:30-13:30 | | Free Communications 13 - Thyroid Chair(s): Michel Polak (Paris, France) Hall 5
|
| 12:30 | FC13.1 | Gain of function STAT3 mutation in a boy with early onset autoimmune diabetes and thyroid disease, prenatal and postnatal growth impairment and lymphoproliferation |
| 12:40 | FC13.2 | Analysis of chosen polymorphisms rs2476601 A/G - PTPN22, rs1990760 C/T - IFIH1, rs179247 A/G - TSHR in pathogenesis of autoimmune thyroid diseases in children |
| 12:50 | FC13.3 | Targeted next-generation sequencing demonstrates high frequency of ‘dyshormonogenesis genes’ mutations in severe congenital hypothyroidism |
| 13:00 | FC13.4 | Effects of initial levothyroxine dose on growth and neurodevelopmental outcomes during the first year of life in children with congenital hypothyroidism |
| 13:10 | FC13.5 | Effect of two years of treatment with levothyroxine on cardiovascular risk factors in children with mild idiopathic subclinical hypothyroidism |
| 13:20 | FC13.6 | TRIAC treatment of allan-herndon-dudley syndrome (AHDS) due to defects in thyroid hormone transporter MCT8 |
| 12:30-13:30 | | Free Communications 14 - Puberty Chair(s): Dolores Rodriquez-Amao & Abdullah Bereket Hall 7
|
| 12:30 | FC14.1 | KLB, encoding the co-receptor for FGF21, is mutated in congenital hypogonadotropic hypogonadism |
| 12:40 | FC14.2 | A mutation in HS6ST1 causes self-limited delayed puberty |
| 12:50 | FC14.3 | The new syndrome of hypogonadotropic hypogonadism, arrythmogenic right ventricular dysplasia, facial dysmorphism and absence of corpus callosum is associated to TAX1 binding protein 3 gene mutation |
| 13:00 | FC14.4 | Genetic variation of AMH signaling affects AMH and inhibin B levels in healthy peripubertal girls |
| 13:10 | FC14.5 | Polybrominated diphenyl ethers (PBDEs) and timing of puberty in girls |
| 13:20 | FC14.6 | An evaluation of glandular breast tissue development and volume by MRI in 121 healthy peripubertal girls |
| 12:30-13:30 | | Free Communications 15 - Late Breaking Chair(s): Carlos Longui & Olle Söder (Stockholm, Sweden) Hall 6
|
| 12:30 | FC-LB-1 | RNA Sequencing Reveals The Pathways Perturbed by Redox Imbalance in Nicotinamide Nucleotide Transhydrogenase null mice. |
| 12:40 | FC-LB-2 | Loss of Neuronal Dmxl2 impairs the maturation and the activation of GnRH neurons: a new mechanism of GnRH deficiency. |
| 12:50 | FC-LB-3 | Pharmacokinetic and Pharmacodynamic Studies of Topicon™-Mediated Patch Delivery of Insulin Glargine in a Streptozotocin-Induced Hairless Rat Model |
| 13:00 | FC-LB-4 | Long-term cognitive effects of antenatal dexamethasone treatment in Swedish adolescents with and without CAH |
| 13:10 | FC-LB-5 | Paternally inherited IGF2 mutation results in intrauterine and postnatal growth retardation |
| 13:20 | FC-LB-6 | PROP1 mutations cause hypopituitarism by disrupting the transition of pituitary stem cells to differentiation |
| 13:30- | | Lunch, Visit to the Posters and Exhibition
|
| 13:30-14:30 | | P1 Mini Poster Presentations
|
| | Diabetes: P1-45 to P1-55 |
| | Fat: P1-67 to P1-77 |
| | Puberty: P1-111 to P1-121 |
| | Thyroid: P1-122 to P1-132 |
| | Misc: P1-155 to P1-165 |
| 13:45-15:15 | | ESPE Education and Training Hall 6
|
| 14:00-15:00 | | Industry Sponsored Satellite Symposium 9
|
| 15:30-17:00 | | Symposium 8 - Diabetes & Obesity as infectious diseases Chair(s): Maria Chueca (Spain) & Zdenek Sumnik (Prague, Czech Republic) Hall 1
|
| 15:30 | S8.1 | Disentangling disease and drug signatures in the human gut microbiome |
| 16:00 | S8.2 | The role of the gut microbiome for immunity and metabolism |
| 16:30 | S8.3 | Gut microbiome modulates the risk for islet autoimmunity |
| 15:30-17:00 | | Symposium 9 - Childhood Craniopharyngioma: Recent Advances Chair(s): Lidia Castro (Santiago de Compostela, Spain) & Helen Spoudeas (London, UK) Hall 2
|
| 15:30 | S9.1 | Outcomes in patients with childhood craniopharyngioma |
| 16:00 | S9.2 | Surgical approach to craniopharyngioma |
| 16:30 | S9.3 | Potential novel therapies for craniopharyngioma: Insights from a mouse model |
| 15:30-17:00 | | Symposium 10 - Growth plate & nutrition Chair(s): Faisal Ahmed (Glasgow, UK) & Agnes Linglart (Paris, France) Hall 4
|
| 15:30 | S10.1 | Molecular mechanisms of growth plate adaptation during undernutrition |
| 16:00 | S10.2 | Molecular response of the growth plate to inflammatory cytokines |
| 16:30 | S10.3 | Bone health in chronic disease |
| 15:30-16:30 | | Meet the Expert Sessions
|
| MTE5.2 | Management of the adolescent with CAH |
| MTE6.2 | Management of Prader-Willi syndrome in toddlers |
| MTE8.2 | Looking beyond nutritional rickets: From the foetus to the infant |
| 17:00-17:30 | | Coffee Break
|
| 17:30-17:45 | | President Poster Award Chair(s): Laura Audí (Barcelona, Spain) Hall 1
|
| 17:45-18:15 | | Plenary 6 Chair(s): Peter Clayton (Manchester, UK) & Mitch Geffner (Los Angeles, UK) Hall 1
|
| 17:45 | PL6 | The complex relationship between the GH/IGF axis and aging and longevity – the interface with diet and mitochondrial peptides |
| 18:15-18:30 | | Closing Ceremony Chair(s): Laura Audí (Barcelona, Spain), Peter Clayton (Manchester, UK) & Jean-Claude Carel (Paris, France) Hall 1
|
| 19:00-23:59 | | ESPE Evening
|